An observational study in IBS (Irritable Bowel Syndrome) and Rosacea, sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Observational
To describe the prevalence of rosacea in a population of patients with IBS followed at a tertiary-level university medical center.
The growing evidence of a correlation between gastrointestinal disorders-particularly irritable bowel syndrome (IBS)-and rosacea suggests the existence of shared pathophysiological mechanisms linked to the gut-skin axis. However, the available data derive primarily from international epidemiological studies, while information obtained from real-world clinical practice in Italy is limited. Therefore, it is of interest to evaluate the prevalence and clinical characteristics of the association between rosacea and IBS in an outpatient population attending a tertiary-level university center, in order to provide observational data useful for better characterizing this patient population.
1,116 studies on the registry are indexed under Irritable Bowel Syndrome; 208 are open to participants now.
This study's planned enrollment of 300 is above the median of 160 across 191 observational studies indexed under Irritable Bowel Syndrome.
Browse Irritable Bowel Syndrome studies →IRCCS Azienda Ospedaliero-Universitaria di Bologna is the lead sponsor of 511 studies on the registry; 287 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study population will consist of all adult patients evaluated in the past 12 months at the outpatient clinics of the Clinical Operational Unit (UOC) of Internal Medicine and Digestive Physiopathology and the Clinical Operational Unit (UOC) of Dermatology at the IRCCS University Hospital of Bologna, Sant'Orsola Polyclinic, with a documented diagnosis of IBS and/or rosacea. Patients for whom both conditions are already documented in their outpatient medical records will be included.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Percentage of patients diagnosed with rosacea among the patients diagnosed with IBS included in the study.
Time frame: 4 months
Distribution of clinical subtypes of rosacea in patients with and without IBS. Age and sex distribution in the two groups. Prevalence of major gastrointestinal comorbidities.
Time frame: 4 months
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Dec 2026, 3 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
IRCCS Azienda Ospedaliero-Universitaria di Bologna →